Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPX-0046 (Enbezotinib) in Advanced Solid Tumors with RET Alterations
NCT04161391Phase 2Terminated
- Sponsor
- Turning Point Therapeutics, Inc.
- Start
- Dec 2019
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of enbezotinib in non-small cell lung cancer (NSCLC), Medullary Thyroid Cancer (MTC), solid tumor, sponsored by Turning Point Therapeutics, Inc.. Started Dec 2019; status: terminated.
02
Drugs
enbezotinib
03
Conditions
non-small cell lung cancer (NSCLC)Medullary Thyroid Cancer (MTC)solid tumor
Beyond the preview
Go deeper on NCT04161391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04161391.